-2.73% for Novo Nordisk stock as rivals pressure obesity drug prices

Traders Union
All News
Financial News
Novo Nordisk drops 2.73% after results

Highlights

Novo Nordisk's 2025 results showed over 10% sales and profit growth, driven by obesity drugs and robust U.S. demand.
Profitability was tempered by GLP-1 competition, pricing pressures, and business transformation, despite the launch of increased dividends and a $2.1 billion buyback.
Technicals signal short-term strength within a broader downtrend, with likely consolidation between $44.00 and $48.00 amid selling pressure and volatility.

Profit growth led by obesity drugs faces pricing and market headwinds

Novo Nordisk released its 2025 financial results, reporting full-year net sales of $43.27 billion and operating profit of $17.88 billion, reflecting over 10% growth at constant exchange rates, with performance primarily boosted by obesity treatments and strong U.S. sales. Operating profit outcomes were shaped by pricing pressures, ongoing transformation costs, and increasing competition in the GLP-1 market. The company also proposed a higher dividend and initiated a $2.1 billion share repurchase program to decrease share capital and fulfill share-based incentive obligations, though price action has remained under broader selling pressure.

Near-overbought signals emerge amid bullish momentum and key support

On the technical side, NVO has recently closed above its SMA-20 at $43.06 and SMA-50 at $39.87, while still trading beneath the longer-term SMA-200 of $49.16. The Ichimoku Kijun level on the daily chart is positioned at $42.31, marking a key support area just below current prices. Momentum indicators present a mixed picture: daily MACD and ADX retain a bullish undertone, while RSI is elevated at 66.48 and CCI exceeds 70, signaling near-overbought conditions. Conversely, Stoch RSI gives a strong sell reading and BBP highlights buyer dominance but warns of overbought territory. The Awesome Oscillator indicates a neutral trend, and the divergence between momentum and oscillators points to short-term uncertainty.

Consolidation likely as breakdown risks overshadow breakout potential

Looking to the next five trading days, NVO is expected to fluctuate within a volatility band of $44.00 to $48.00 relative to the current price. The prevailing scenario anticipates consolidation between immediate support at $42.31 and resistance near $48.00, reflecting sideways action. There is an increased risk of further price declines, while a sustained upward breakout above $48.00 is considered unlikely, with a probability of less than 20%. Should NVO fall below the $44.00 mark, accelerated selling toward lower support levels may follow.

Viktoras Karapetjanc, Analyst at Traders Union, sees Novo Nordisk’s fundamentals as constructive after robust 2025 financials and decisive capital return actions. He believes structural demand for obesity treatments and the U.S. market remain key positives, though short-term profit headwinds and overbought technical readings may weigh on sentiment. While a breakout above $48.00 appears unlikely for now, he expects the share to consolidate, underpinned by strong fundamentals. "The backdrop stays supportive if buyers defend $44.00 — I see consolidation as a healthy pause before renewed upside opportunities."

Earlier, analysts noted that Novo Nordisk was likely to remain in a period of consolidation amid persistent overbought technical signals and limited prospects for an immediate breakout. With fresh financial results now published and technicals indicating ongoing uncertainty, attention should turn to whether price action can sustain above the $44.00 support zone or if a break lower will trigger deeper short-term retracement.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.